Early On-Treatment Dynamics of HIF-1α after the 10th Radiotherapy Fraction: Paired Pre–Post IHC Study across Breast Cancer Molecular
Penulis / Author
Detail Publikasi
International Journal of Veterinary Science
Unique Scientific Publishers
15
4
1108-1114
2305-4360
Abstrak
Tumor hypoxia, regulated by hypoxia-inducible factor-1α (HIF-1α), is a central mediator of radioresistance in breast cancer. Although baseline HIF-1α has been studied as a prognostic marker, early on-treatment dynamics of HIF-1α during fractionated radiotherapy across molecular subtypes remain poorly characterized. This study aims to evaluate changes in tumor HIF-1α expression between baseline (pre-RT) and after the 10th radiotherapy fraction (post-RT fraction 10), and to assess whether changes differ across IHC-defined molecular subtypes. This prospective observational paired pre–post study included invasive breast cancer patients with available paired FFPE tissue (pre-RT and post-fraction-10). HIF-1α expression was quantified as the percentage of positive tumor cells on IHC. Molecular subtypes (Luminal A, Luminal B, HER2-enriched, triple-negative) were assigned using IHC surrogates with a Ki-67 cut-off of 20 %. Changes were expressed as ΔHIF (post–pre) and %ΔHIF. Between-subtype comparisons were assessed using one-way ANOVA (or non-parametric equivalents as appropriate). Forty-four patients were included (mean age 50.07 ± 9.77 years; 97.7 % female). HIF-1α decreased after fraction 10 across subtypes. Mean ΔHIF (95 % CI) was −6.91 (−11.73 to −2.09) for Luminal A, −5.66 (−7.54 to −3.78) for Luminal B, −4.57 (−8.35 to −0.79) for HER2-enriched, and −2.86 (−7.26 to 1.54) for triple-negative. Between-subtype differences were not statistically significant for ΔHIF (P = 0.400) or %ΔHIF (P = 0.348). As a preliminary, exploratory finding, tumor HIF-1α expression showed an early decrease by the 10th radiotherapy fraction across all IHC-defined molecular subtypes. The magnitude of change did not significantly differ by subtype, suggesting early HIF-1α modulation may represent a shared on-treatment microenvironmental response rather than a subtype-specific phenomenon. These exploratory findings require validation in larger, prospective, multi-center cohorts, but support further evaluation of HIF-1α as an on-treatment biomarker of early radiotherapy response.
Dana Insentif
B.2 - (Q2) WOS IF 0,5-0,9
Rp 20.000.000
Dana Disetujui
Rp 20.000.000
Dicairkan
04 Nov 2026
Alur Proses
Klaim Diajukan
27 Jul 2026Verifikasi Fakultas
27 Jul 2026Verifikasi Rektorat
12 Oct 2026Verifikasi Sekretaris
06 Aug 2026Disetujui Ka LPPM
06 Aug 2026Dana Dicairkan
04 Nov 2026Informasi Dosen
Meta Zulyati Oktora
NIDN: 1002108502
Lektor
Profil Akademik